Oncotype DX is the only genomic test validated to predict whether patients with early-stage invasive breast cancer are likely to benefit from chemotherapy. It is also designed to gauge the overall risk of breast cancer recurrence over a 10-year time span.
http://ift.tt/eA8V8J
0 comments:
Post a Comment